Boston BioPharm

Boston BioPharm, founded July 2011, is a global Pharmaceutical, OTC, Medical Foods, and Dietary Ingredient leader in the field of formulation technology, including over 9 patents, continuation, and divisional patents centered around the patent protected BioSolusperse™ formulation platform. Our teams are industry leading scientist, medical doctors, and business professionals with over 100 years of combined product development, regulatory compliance, formulary, diagnostics, and marketing and distribution expertise. Applying our deep scientific and regulatory compliance expertise, we are driven to efficiency and excellence in all phases of product development; ingredient/API identification, early development through to commercialization. We are driven by science, clinical trials, and efficacy – our statistically significant absorption and efficacy is known in our industry regarding our therapeutics. Understanding the immediate need for testing, Boston BioPharm partnered with GeneMatrix, under an exclusive license for the NeoPlex™ line of diagnostic products, in North/South America and Europe to help save lives. GeneMatrix, founded December 2000, is a global biotechnology leader in the field of molecular diagnostics. GeneMatrix developed and owns several patented molecular diagnostic technologies, including C-TAG, Omniplex, EnCleap, TriO, REMP which have been applied to diseases such as hepatitis B and C, cervical cancer, sexually transmitted infections, gastrointestinal infections and respiratory infections including influenza. GeneMatrix has pioneered an approved KFDA, FDA, CE-IVD NeoPlex™ Covid-19 Detection Kit with clinical detection results shown to be 100% accurate.